| Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. |
| Novel Drug for Chronic Management of Hyperuricemia in Gout Patients Teijin Pharma Limited announced the European launch of TMX-67 (febuxostat), a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. Ipsen, a global biotechnology specialty care group and the TMX-67 licensee in Europe, and its sublicensee the Menarini Group, the first Italian pharmaceutical group in the world, have began marketing the product in Europe under the brand name ADENURIC(r). |
| Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZAâ?˘ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors. |
| Google Announces Public Data Explorer Google announces an addition to Google Labs - the Public Data Explorer. The purpose of the new tool, Google says on the new lab's page, "The Google Public Data Explorer makes large datasets easy to explore, visualize and communicate. |
| MitoTarget Launches New Online Resource for Physicians and Sufferers from Rare Illness ALS Trophos, the pharmaceutical company specialising in therapies for orphan diseases including ALS (also known as Lou Gehrig's disease), announces, on behalf of the MitoTarget consortium, the launch of MitoTarget Online. The multilingual web-based resource aims to be the first point of call for all of those affected by ALS. |
| EU-funded researchers sequence human gut microbe genome EU-funded researchers have sequenced the genome of the community of microbes that lives in our guts. The study sheds new light on the influence of these microbes on our health and could lead to the development of new treatments and diagnostic tests for a variety of diseases. |
| Physicians Will Expand Range of Mobile Activities to Include Administrative and Patient Care Tasks Physicians will significantly expand the range of activities they conduct on mobile devices by 2012, according to Manhattan Research's "Future of Physician Media" report. Currently physicians primarily use mobile devices to access clinical content and perform quick tasks. |
| Web Innovators, Pharma, Insurance and Government Converge to Speak at Health 2.0 Europe 6-7 April 2010, Paris, France. Health 2.0 Europe, a conference dedicated to how Web 2.0 and social media are transforming healthcare systems in Europe, has finalized its agenda and speaker list. Encompassing all aspects of the healthcare chain, the interactive program will address healthcare on both country- and European-wide levels, with local experts from converging industries. |
| Lundbeck delivers 22 percent revenue growth for 2009 H. Lundbeck A/S (Lundbeck) announces 2009 results, which meet financial forecasts and continue to show growth in all regions. Full year revenue was DKK 13,747 million and increased 22% at constant exchange rates compared to 2008. |
| Bristol-Myers Squibb and Allergan Enter Global Agreement Bristol-Myers Squibb Company (NYSE: BMY) and Allergan, Inc. (NYSE: AGN) announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain. |
The content of these articles do not reflect the opinion of Triple i, MediMedia USA, or their employees.